pharmaphorum Podcast

 In the latest instalment of the pharmaphorum podcast, Editor in Chief Jonah Comstock connects with Kylie O’Keefe to talk about gene therapy in rare diseases. 

They discuss what different gene therapies have in common and how some particular therapies work. They also talk about what gene therapy means for the industry and for patients, in particularly the paradigm shift of disease-modifying therapies. 

On 21st June, London’s prestigious Royal Society of Medicine will play host to some of the sharpest minds in healthcare as they come together for the inaugural World Without Disease conference, developed by pharmaphorum and the CWWDA.

One of these minds is Daniel Zakowski, CEO of Ready, Set, Food!, who will be taking the stage to discuss why preventing childhood food allergies is an important step in the journey towards the vision of a disease-free world.

Having any chronic health condition is complicated, difficult, and scary. But add in a cultural or social stigma and you create whole new levels of challenge. 

In today’s pharmaphorum podcast, brought to you by Cerner Enviza, an Oracle company, editor in chief Jonah Comstock welcomes Nate Way, senior evidence generation lead at Cerner Enviza and James Geary MBA, MHA, a data analyst who also lives with Cerebral Palsy and anxiety and depression.  

In this latest mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Tommy Bramley, SVP of global consulting at Amerisource Bergen, whilst attending Reuters Pharma Barcelona.

On today’s pharmaphorum podcast, Evidation’s Executive Chair of the Board Deborah Kilpatrick joins host Jonah Comstock to talk about healthcare data collection in 2023 and how it intersects with stakeholders across the ecosystem, from tech and pharma companies to research participants. 

In this new episode of the mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Simon Powell, CEO of Ribonexus, a new company put together to develop and ultimately commercialise long-standing research programmes from Gustav Roussy, Institut Curie, the University of Strasbourg, and Pierre Fabre, to develop drugs that overcome tumour resistance to existing drug treatments.

In today’s pharmaphorum podcast, brought to you by Lannett Corporation, editor in chief Jonah Comstock first chats with Timothy Crew, CEO of Lannett. Crew talks about the contract development manufacturing organisation (CDMO) business and why local manufacturing is important in the United States.

Then, in part 2, Jonah talks to Tom Lewis, Lannett’s VP of Global Supply Chain and CDMO Management. They discuss Lannett’s CDMO business more broadly, how it works, and why it’s an important offering in today’s pharma landscape.

Almost everyone seems to agree that drug prices are too high. But that agreement stops when it comes to the question of why they’re so high, and to the question of how to bring them down. 

Goodroot CEO Mike Waterbury and Nuwae Health CEO Ralph Pisano discuss how the community of Goodroot companies, including Nuwae, are attacking that issue from different angles. 

Angelini Ventures is a recently launched investment fund seeking companies that are transformational in healthcare. Founder of pharmaphorum and Healthware Group's chief content officer, Paul Tunnah, talks with Nils Bottler, who recently joined Angelini Ventures as Principal, about his career and where Angelini Ventures aims to have an impact.

For the newest pharmaphorum podcast, editor in chief Jonah Comstock welcomes Dr. Kristina Allikmets, SVP and head of R&D at Takeda’s plasma-derived therapies business unit.